Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 4:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 5,020 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Additional Therapies Clear all
Recruiting Phase 1 Interventional

Venetoclax Basket Trial for High Risk Hematologic Malignancies

NCT05292664
View directory record Official record
Conditions
Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary, Myelodysplastic Syndromes, Previously Treated, Treatment-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Lymphoblastic Lymphoma, in Relapse, Lymphoblastic Lymphoma, Refractory, Acute Leukemia of Ambiguous Lineage in Relapse, Acute Leukemia of Ambiguous Lineage
Interventions
Venetoclax, Azacitidine, Cytarabine, Methotrexate, Hydrocortisone, Leucovorin, Dexamethasone, Vincristine, Doxorubicin, Dexrazoxane, Calaspargase Pegol, Erwinia asparaginase
Drug
Lead sponsor
Andrew E. Place, MD
Other
Eligibility
1 Year to 40 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
5
States / cities
San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 3, 2026, 4:21 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Prospective Effect of Intravenous Ketorolac on Opioid Use, EBL and Complications Following Cesarean Delivery

NCT02509312
View directory record Official record
Conditions
Analgesia, Obstetrical, Postpartum Hemorrhage, Opioid Use, Nonsteroidals (NSAIDs)Toxicity, Coagulation Defect; Postpartum, Postoperative Pain, Ketorolac Adverse Reaction, Blood Loss, Postoperative
Interventions
Ketorolac, Placebo
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Oct 3, 2026, 4:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Automated & Coached Web-based Programs to Improve and Strengthen Romantic Relationships

NCT03568565
View directory record Official record
Conditions
Relationship, Marital
Interventions
ePREP Program, OurRelationship Program
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 64 Years
Enrollment
2,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Sep 14, 2020 · Synced Oct 3, 2026, 4:21 AM EDT
Completed Phase 1 Interventional

Safety Study to Evaluate KW-2450 in Subjects With Advanced Solid Tumor

NCT00921336
View directory record Official record
Conditions
Solid Tumor
Interventions
KW-2450
Drug
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Baltimore, Maryland • Detroit, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 3, 2026, 4:21 AM EDT
Recruiting Not applicable Interventional

Heart Coherence Training on Vascular Ehlers-Danlos Syndrome Patients

NCT05994664
View directory record Official record
Conditions
Vascular Ehlers-Danlos Syndrome
Interventions
Heartmath Intervention, Control Group
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 3, 2026, 4:21 AM EDT
Recruiting Phase 3 Interventional

Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes

NCT06246799
View directory record Official record
Conditions
Type 2 Diabetes (Adult Onset)
Interventions
Tirzepatide, Pioglitazone, Sitagliptin, Metformin HCI XR
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 75 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 3, 2026, 4:21 AM EDT
Completed Phase 2 Interventional Results available

Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma

NCT03620019
View directory record Official record
Conditions
Melanoma Stage Iii, Melanoma Stage Iv, Melanoma, Melanoma (Skin), Cutaneous Melanoma
Interventions
Denosumab, Pembrolizumab, Nivolumab
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Manchester, New Hampshire • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 3, 2026, 4:21 AM EDT
Not listed Not applicable Interventional

Stress-Reducing Interventions in HIV+ Patients: Pilot

NCT00599599
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic, HIV Infections
Interventions
Prolonged Exposure Therapy
Behavioral
Lead sponsor
Kent State University
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
2
States / cities
Akron, Ohio • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2009 · Synced Oct 3, 2026, 4:21 AM EDT
Completed Not applicable Interventional

mHealth for Diabetes Adherence Support

NCT02990299
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
mHealth for Diabetes Adherence Support
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
21 Years to 75 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 3, 2026, 4:21 AM EDT
Completed Phase 3 Interventional Results available

Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome

NCT02132195
View directory record Official record
Conditions
Nephrotic Syndrome
Interventions
ACTH
Drug
Lead sponsor
Emory University
Other
Eligibility
2 Years to 20 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Wilmington, Delaware + 13 more
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 3, 2026, 4:21 AM EDT
Completed Phase 2 Interventional

Drug Treatment for Alcoholics With Bipolar Disorder

NCT00000439
View directory record Official record
Conditions
Alcoholism, Bipolar Disorder
Interventions
sodium valproate
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 3, 2026, 4:21 AM EDT
Completed Not applicable Interventional

Feasibility of a Health Care Provider Guided Exercise Intervention Prior to Surgical Resection of Pancreatic Cancer

NCT05483075
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
HCP-Guided Exercise Training Program
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 3, 2026, 4:21 AM EDT
Completed No phase listed Observational Results available

MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301

NCT02952001
View directory record Official record
Conditions
Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate, Panuveitis
Interventions
4 mg CLS-TA Suprachoriodal Injection, Sham procedure
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
Phoenix, Arizona • Mountain View, California • Fort Lauderdale, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Oct 3, 2026, 4:21 AM EDT
Completed Phase 2 Interventional Results available

Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART

NCT01903031
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Nuvaring, EFV, ATV/r, TDF, NRTIs
Device · Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
16 Years and older · Female only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 3, 2026, 4:21 AM EDT
Completed Phase 1 Interventional

Study of GS-3242 in Participants With HIV-1; Substudy-05

NCT07001319
View directory record Official record
Conditions
HIV-1-infection
Interventions
GS-3242, BVY, Standard of Care
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
21
States / cities
Bakersfield, California • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 3, 2026, 4:21 AM EDT
Completed Phase 4 Interventional Results available

Serotonin Selective Reuptake Inhibitor Treatment of Dual Diagnosis Post-traumatic Stress Disorder and Alcohol Problems

NCT02504931
View directory record Official record
Conditions
PTSD, Alcohol Use Disorder
Interventions
Sertraline, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
21 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Oct 3, 2026, 4:21 AM EDT
Recruiting Phase 1 Interventional

Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma

NCT06815029
View directory record Official record
Conditions
Recurrent Astrocytoma, IDH-Mutant, Grade 3, Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma
Interventions
Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy, Echocardiography, Fludeoxyglucose F-18, Intracranial Catheter Placement, Leukapheresis, Magnetic Resonance Imaging, Positron Emission Tomography, Resection
Procedure · Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 3, 2026, 4:21 AM EDT
Terminated Not applicable Interventional

Feasibility, Safety, and Efficacy of Stereotactic MRI-Guided Adaptive Radiation Therapy (SMART) for Central Lung Tumors

NCT05609331
View directory record Official record
Conditions
Lung Cancer
Interventions
Simulated Online Adaptive Planning, Stereotactic MRI-guided adaptive radiotherapy-SMART
Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 3, 2026, 4:21 AM EDT
Terminated Not applicable Interventional

RCT of Caloric Restriction vs. Alternate-Day Fasting in Non-Alcoholic Fatty Liver Disease

NCT03365531
View directory record Official record
Conditions
NAFLD, Obesity, Diabetes Mellitus, Type 2
Interventions
Alternate Daily Fasting (ADF), Caloric Restriction (CR)
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Oct 3, 2026, 4:21 AM EDT
Terminated Phase 3 Interventional

GALLANT 9 Tesaglitazar vs. Placebo in Combination With Insulin

NCT00242372
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Tesaglitazar 0.5, Insulin at least 30 units/day
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
71
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tuscson, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2009 · Synced Oct 3, 2026, 4:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Physical Therapy in Addition to Standard Care Following C-Section

NCT02804139
View directory record Official record
Conditions
Low Back Pain, Pelvic Pain, Scar Tissue, Adhesions
Interventions
Standard care plus physical therapy, Standard Care
Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older · Female only
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 3, 2026, 4:21 AM EDT
Completed Phase 2Phase 3 Interventional

African American Study of Kidney Disease and Hypertension ABPM Pilot Study

NCT00582777
View directory record Official record
Conditions
Hypertensive Renal Disease
Interventions
USUAL - take your BP Meds as you usually do, HS DOSING, ADD On Dosing
Behavioral · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2012 · Synced Oct 3, 2026, 4:21 AM EDT
Terminated Phase 4 Interventional Results available

Immune Tolerance Induction Study

NCT00701701
View directory record Official record
Conditions
Pompe Disease, Glycogen Storage Disease Type II (GSD-II), Glycogenesis 2 Acid Maltase Deficiency
Interventions
Myozyme® (alglucosidase alfa)
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
1 Month and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
4
States / cities
Louisville, Kentucky • Durham, North Carolina • Salt Lake City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Oct 3, 2026, 4:21 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial)

NCT01023477
View directory record Official record
Conditions
Carcinoma, Intraductal, Noninfiltrating, DCIS, Ductal Carcinoma In Situ
Interventions
Chloroquine Standard Dose (500mg/week), Chloroquine Low Dose (250mg/week), Breast Biopsy
Drug · Procedure
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
4
States / cities
Fairfax, Virginia • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Oct 3, 2026, 4:21 AM EDT